Moreover, the 36-month beta value for VERV is 1.87. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VERV is 66.18M and currently, short sellers hold a 23.08% of that float. On April 02, 2025, VERV’s average trading volume was 1.44M shares.
VERV) stock’s latest price update
The stock price of Verve Therapeutics Inc (NASDAQ: VERV) has plunged by -9.52 when compared to previous closing price of 4.57, but the company has seen a -29.20% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-24 that BOSTON, March 24, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C).
VERV’s Market Performance
Verve Therapeutics Inc (VERV) has seen a -29.20% fall in stock performance for the week, with a -32.98% decline in the past month and a -31.31% plunge in the past quarter. The volatility ratio for the week is 8.54%, and the volatility levels for the past 30 days are at 9.15% for VERV. The simple moving average for the last 20 days is -28.59% for VERV stock, with a simple moving average of -30.84% for the last 200 days.
Analysts’ Opinion of VERV
Many brokerage firms have already submitted their reports for VERV stocks, with H.C. Wainwright repeating the rating for VERV by listing it as a “Buy.” The predicted price for VERV in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on April 08, 2024 of the previous year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see VERV reach a price target of $29. The rating they have provided for VERV stocks is “Buy” according to the report published on April 13th, 2023.
Cantor Fitzgerald gave a rating of “Neutral” to VERV, setting the target price at $21 in the report published on February 01st of the previous year.
VERV Trading at -39.36% from the 50-Day Moving Average
After a stumble in the market that brought VERV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.77% of loss for the given period.
Volatility was left at 9.15%, however, over the last 30 days, the volatility rate increased by 8.54%, as shares sank -32.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.65% lower at present.
During the last 5 trading sessions, VERV fell by -29.20%, which changed the moving average for the period of 200-days by -26.03% in comparison to the 20-day moving average, which settled at $5.79. In addition, Verve Therapeutics Inc saw -26.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERV starting from Dorval Allison, who sale 555 shares at the price of $5.64 back on Dec 02 ’24. After this action, Dorval Allison now owns 5,380 shares of Verve Therapeutics Inc, valued at $3,130 using the latest closing price.
Ashe Andrew D., the of Verve Therapeutics Inc, purchase 76,000 shares at $6.26 during a trade that took place back on May 14 ’24, which means that Ashe Andrew D. is holding 342,509 shares at $475,760 based on the most recent closing price.
Stock Fundamentals for VERV
Current profitability levels for the company are sitting at:
- -7.07 for the present operating margin
- 0.84 for the gross margin
The net margin for Verve Therapeutics Inc stands at -6.15. The total capital return value is set at -0.38. Equity return is now at value -36.36, with -28.39 for asset returns.
Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.25.
Currently, EBITDA for the company is -228.66 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 8.18. The receivables turnover for the company is 9.93for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.65.
Conclusion
To wrap up, the performance of Verve Therapeutics Inc (VERV) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
